We demonstrate the successful application of exome sequencing 1-3 to discover a gene for an autosomal dominant disorder, Kabuki syndrome (OMIM%147920). We subjected the exomes of ten unrelated probands to massively parallel sequencing. After filtering against existing SNP databases, there was no compelling candidate gene containing previously unknown variants in all affected individuals. Less stringent filtering criteria allowed for the presence of modest genetic heterogeneity or missing data but also identified multiple candidate genes. However, genotypic and phenotypic stratification highlighted MLL2, which encodes a Trithoraxgroup histone methyltransferase 4 : seven probands had newly identified nonsense or frameshift mutations in this gene. Follow-up Sanger sequencing detected MLL2 mutations in two of the three remaining individuals with Kabuki syndrome (cases) and in 26 of 43 additional cases. In families where parental DNA was available, the mutation was confirmed to be de novo (n = 12) or transmitted (n = 2) in concordance with phenotype. Our results strongly suggest that mutations in MLL2 are a major cause of Kabuki syndrome.
Kabuki syndrome is a rare, multiple malformation disorder characterized by a distinctive facial appearance (Supplementary Fig. 1 ), cardiac anomalies, skeletal abnormalities, immunological defects and mild to moderate mental retardation. Originally described in 1981 (refs. 5,6) , Kabuki syndrome has an estimated incidence of 1 in 32,000 (ref. 7) , and approximately 400 cases have been reported worldwide. The vast majority of reported cases have been sporadic, but parent-tochild transmission in more than a half dozen instances 8 suggests that Kabuki syndrome is an autosomal dominant disorder. The relatively low number of cases, the lack of multiplex families and the phenotypic variability of Kabuki syndrome have made the identification of the gene(s) underlying this disorder intractable to conventional approaches of gene discovery, despite aggressive efforts.
We sequenced the exomes of ten unrelated individuals with Kabuki syndrome: seven of European ancestry, two of Hispanic ancestry and one of mixed European and Haitian ancestry ( Supplementary Fig. 1 and Supplementary Table 1) . Enrichment was performed by hybridization of shotgun fragment libraries to custom microarrays followed by massively parallel sequencing [1] [2] [3] . On average, 6.3 gigabases of sequence were generated per sample to achieve 40× coverage of the mappable, targeted exome (31 Mb). As with our previous studies, we focused our analyses here primarily on nonsynonymous variants, splice acceptor and donor site mutations and coding indels, anticipating that synonymous variants were far less likely to be pathogenic. We also predicted that variants underlying Kabuki syndrome are rare, and therefore likely to be previously unidentified. We defined variants as previously unidentified if they were absent from all datasets used for comparison, including dbSNP129, the 1000 Genomes Project, exome data from 16 individuals previously reported by us 2,3 and 10 exomes sequenced as part of the Environmental Genome Project (EGP). Under a dominant model in which each case was required to have at least one previously unidentified nonsynonymous variant, splice acceptor and donor site mutation or coding indel variant in the same gene, only a single candidate gene (MUC16) was shared across all ten exomes ( Table 1 and Supplementary Table 2) . However, we considered MUC16 as a likely false positive due to its extremely large size (14,507 amino acids). Potential explanations for our failure to find a compelling candidate gene in which newly identified variants were seen in all affected individuals included: (i) Kabuki syndrome is genetically heterogeneous and therefore not all affected individuals will have mutations in the same gene; (ii) we failed to identify all mutations in the targeted exome; and (iii) some or all causative mutations were outside of the targeted exome, for example, in noncoding regions or unannotated genes. To allow for a modest degree of genetic heterogeneity and/or missing data, we conducted a less stringent analysis by looking for candidate genes shared among subsets of affected individuals. Specifically, we searched Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome for subsets of x out of 10 exomes having ≥1 previously unidentified variant in the same gene, with x = 1 to x = 10. For x = 9, x = 8 and x = 7, previously unidentified variants were shared in 3 genes, 6 genes and 16 genes, respectively ( Table 1) . However, there was no obvious way to rank these candidate genes.
We speculated that genotypic and/or phenotypic stratification would facilitate the prioritization of candidate genes identified by subset analysis. Specifically, we assigned a categorical rank to each individual with Kabuki syndrome based on a subjective assessment of the presence of, or similarity to, the canonical facial characteristics of Kabuki syndrome (Supplementary Fig. 1 ) and the presence of developmental delay and/or major birth defects (Supplementary Table 1 ). The highest-ranked individual was one of a pair of monozygotic twins with Kabuki syndrome. We then categorized the functional impact (that is, nonsense versus nonsynonymous substitution, splice-site disruption and frameshift compared to in-frame indel) of each newly identified variant in candidate genes shared by each subset of two or more ranked cases. Manual review of these data highlighted distinct, previously unidentified nonsense variants in MLL2 in each of the four highest-ranked cases. After sequential analysis of phenotype-ranked cases with a loss-of-function filter, MLL2 was the only candidate gene remaining after addition of the second individual ( Table 2) . We found no such variant in MLL2 in the individual with Kabuki syndrome ranked fifth; hence, the number of candidate genes dropped to zero after the individual ranked fourth in the set ( Table 2) . However, we found a 4-bp deletion in the individual ranked sixth, and we found nonsense variants in the individuals ranked seventh and ninth. Thus, exome sequencing identified a nonsense substitution or frameshift indel in MLL2 in seven of the ten individuals with Kabuki syndrome analyzed here.
Retrospectively, we applied a loss-of-function filter to the subset analysis of exome data ( Table 1) , and at x = 7, found MLL2 to be the only candidate gene. We also developed a post hoc ranking of candidate genes based on the functional impact of the variants present (variant score) and the rank of the cases in which each variant was observed (case score). When this was applied to the exome data as a combined metric, MLL2 emerged as the top candidate gene (Supplementary Fig. 2 ).
In parallel with these analyses, we applied genomic evolutionary rate profiling (GERP) 9 to the exome data. GERP uses mammalian genome alignments to define a rejected substitution score for each variant regardless of functional class. We have previously shown that the quantitative ranking of candidate genes by the rejected substitution scores of their variants can facilitate the exome-based analysis of Mendelian disorders 10 . Following subset analysis with GERP-based ranking, MLL2 remained on the candidate list up to x = 8, ranking third in a list of 11 candidate genes at this threshold ( Table 3 and Supplementary Fig. 3) . Notably, the additional MLL2 variant contributing to this analysis (such that MLL2 was still considered at x = 8) was a synonymous substitution with a rejected substitution score of 0.368 in the individual ranked fifth.
We sought to confirm all newly identified variants in MLL2, particularly because lossof-function variants identified through massively parallel sequencing have a high prior probability of being false positives. All seven loss-offunction variants in MLL2 were validated by Sanger sequencing. We further analyzed the three cases in which we did not initially find a loss-of-function variant in MLL2, first by array comparative genomic hybridization (aCGH) to determine any gross structural changes and then by Sanger sequencing of all exons of MLL2 in case of false negatives by exome sequencing. Because an average of 96% of the coding bases in MLL2 were called at sufficient quality and coverage for single nucleotide variant detection, we anticipated that any missed variants were more likely to be indels because of the higher coverage required for confident indel detection in short-read sequence data. Indeed, although aCGH did not find any structural variants in the region, Sanger sequencing did identify frameshift indels in two of these three cases (specifically, the cases ranked eighth and tenth).
Ultimately, loss-of-function mutations in MLL2 were identified in nine out of ten cases in the discovery cohort (Fig. 1) , making this gene a compelling candidate for Kabuki syndrome. For validation, we screened all 54 exons of MLL2 in 43 additional cases by Sanger sequencing. Previously unidentified nonsynonymous, nonsense or frameshift mutations in MLL2 were found in 26 of these 43 cases ( Fig. 1 and  Supplementary Table 3 ). In total, through either exome sequencing or targeted sequencing of MLL2, 33 distinct MLL2 mutations were identified in 35 of 53 families (66%) with Kabuki syndrome (Fig. 1 and  Supplementary Table 3) . In each of 12 cases for which DNA from both parents was available, the MLL2 variant was found to have occurred de novo. Three mutations were found in two individuals each. One of these three mutations was confirmed to have arisen de novo in one of the cases, indicating that some mutations in individuals with Kabuki syndrome are recurrent. In addition, MLL2 mutations (resulting in p.4527K>X and p.5464T>M) were also identified in each of two families in which Kabuki syndrome was transmitted from parent to child. Variants were filtered as in table 1. Exomes were added sequentially to the analysis by ranked phenotype; for example, column "+3" shows the number of genes at the intersection of the three top ranked cases (supplementary Fig. 1 ).
The gene with at least one NS/SS/I in all individuals is MUC16, which is very likely to be a false positive due to its extreme length (14,507 amino acids).
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Our results strongly suggest that mutations in MLL2 are a major cause of Kabuki syndrome. MLL2 encodes a large 5,262-residue protein that is part of the SET family of proteins, of which Trithorax, the Drosophila homolog of MLL, is the best characterized 11 . The SET domain of MLL2 confers strong histone 3 lysine 4 methyltransferase activity and is important in the epigenetic control of active chromatin states 12 . In mice, loss of Mll2 on a mixed 129Sv/C57BL/6 background slows growth, increases apoptosis and retards development, leading to early embryonic lethality due in part to misregulation of homeobox gene expression 13 . However, no morphological defects have been reported in Mll2 +/− mice 13 .
Most of the MLL2 variants identified in individuals with Kabuki syndrome are predicted to truncate the polypeptide chain before translation of the SET domain. Though it is not certain whether Kabuki syndrome results from haploinsufficiency or from a gain of function at MLL2, haploinsufficiency seems to be the more likely mechanism. Deletion of chromosome 12q12-q13.2, which encompasses MLL2, has been reported in a child with characteristics of Noonan syndrome 14 . However, we re-analyzed this case using oligo aCGH (including 21 probes that cover MLL2) and found the distal breakpoint to be located ~700 kb proximal to MLL2 (data not shown). Also, all of the pathogenic missense variants identified here are located in regions of MLL2 that encode C-terminal domains. This suggests that missense variants elsewhere in MLL2 may be better tolerated or, alternatively, may be embryonically lethal.
For the 18 of 53 cases for which no previously unidentified protein-altering variant was found, it is possible that noncoding or other missed mutations in MLL2 are responsible for this disorder. Alternatively, Kabuki syndrome could be genetically heterogeneous, and further analysis of these cases by exome sequencing may elucidate additional genes for Kabuki syndrome and potentially explain some of the phenotypic heterogeneity seen in this disorder. Notably, 9 of 10 individuals in the discovery cohort (90%), but only 26 of 43 individuals in the replication cohort (60%), were ultimately found to have mutations in MLL2. It is therefore possible that the careful selection of canonical Kabuki cases for the discovery cohort enriched for a shared genetic basis. This underscores the importance of access to deeply phenotyped and well-characterized cases.
In summary, we applied exome sequencing of a small number of unrelated individuals with Kabuki syndrome to discover that mutations in MLL2 underlie this disorder. As predicted in previous analyses 2, 3 , allowing for even a small degree of genetic heterogeneity or missing data substantially confounds exome analysis by increasing the number of candidate genes consistent with the model of inheritance. To facilitate the prioritization of genes under such criteria, we stratified data by ranked phenotypes and found that MLL2 was prominent in the higher ranked cases. However, nine of the ten individuals with Kabuki syndrome in the discovery cohort were ultimately found to have MLL2 mutations, such that stratification by phenotype was of less importance than originally appeared to have been the case. Nonetheless, the sequential analysis of ranked cases may have reduced the probability of confounding due to genetic heterogeneity. All of the MLL2 mutations found in the discovery set via exome sequencing were loss-of-function variants. As a result, MLL2 ranked highly among candidate genes assessed by predicted functional impact. Such a pattern will likely occur for some, but not all, Mendelian phenotypes subjected to this approach. We anticipate that the further development of strategies to stratify data at both the genotypic and phenotypic level will be critical for exome and whole-genome sequencing to reach their full potential as tools for discovery of genes underlying Mendelian and complex diseases. The number of genes with at least a single previously unidentified variant with a rejected substitution score 10 > 0 in at least x individuals is given. A gene rank is assigned based on the average GERP score 9 over all newly identified variants with rejected substitution score > 0 in all affected individuals. Figure 1 Genomic structure and allelic spectrum of MLL2 mutations that cause Kabuki syndrome. MLL2 is composed of 54 exons that encode untranslated regions (orange) and protein coding sequence (blue) including 7 PHD fingers (yellow), FYRN (green), FYRC (green) and a SET domain (red). Arrows indicate the locations of 32 different mutations found in 53 families with Kabuki syndrome including 20 nonsense mutations, 7 indels and 5 amino acid substitutions. Asterisks indicate mutations that were confirmed to be de novo and crosses indicate cases for which parental DNA was unavailable. The two underlined mutations were transmitted each within a family, from an affected parent to an affected child. l e t t e r s MeTHODS Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Accession codes. Exome data for the discovery cohort is available via the NCBI dbGaP repository under accession number phs000295.v1.p1.
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Cases and samples. For exome sequencing, we selected ten individuals of self-reported European, Hispanic or mixed European and Haitian ancestry with Kabuki syndrome from ten unrelated families. Phenotypic data were collected from review of medical records, phone interviews and photographs. All participants provided written consent, and the Institutional Review Boards of Seattle Children's Hospital and the University of Washington approved all studies. The clinical characteristics of the 43 individuals in the validation cohort who had been diagnosed with Kabuki syndrome have been reported previously 7 . Subjective assessment and ranking of the Kabuki phenotype was based on pictures of each subject (Supplementary Fig. 1 ) and clinical information (Supplementary Table 1) . Informed consent was obtained for publication of each of the facial photos shown.
Exome definition, array design and target masking. We targeted all protein-coding regions as defined by RefSeq 36.3. Entries were filtered for the following: (i) CDS as the feature type, (ii) transcript name starting with "NM_" or "-", (iii) reference as the group_label, (iv) not being on an unplaced contig (for example, 17|NT_113931.1). Overlapping coordinates were collapsed for a total of 31,922,798 bases over 186,040 discontiguous regions. A single custom array (Agilent, 1M features, aCGH format) was designed to have probes over these coordinates as previously described 3 , except here, the maximum melting temperature (T m ) was raised to 73 °C.
The mappable exome was also determined as previously described 3 using this RefSeq exome definition instead. After masking for 'unmappable' regions, 30,923,460 bases were left as the mappable target.
Targeted capture and massive parallel sequencing. Genomic DNA was extracted from peripheral blood lymphocytes using standard protocols. Five micrograms of DNA from each of ten individuals with Kabuki syndrome was used for construction of a shotgun sequencing library as described previously 3 using paired-end adaptors for sequencing on an Illumina Genome Analyzer II (GAII). Each shotgun library was hybridized to an array for target enrichment; this was then followed by washing, elution and additional amplification. Enriched libraries were then sequenced on a GAII to get either single-end or paired-end reads.
Read mapping and variant analysis. Reads were mapped and processed largely as previously described 3 . In brief, reads were quality recalibrated using Eland and then aligned to the reference human genome (hg18) using Maq. When reads with the same start site and orientation were filtered, paired-end reads were treated like separate single-end reads; this method is overly conservative and hence the actual coverage of the exomes is higher than reported here. Sequence calls were performed using Maq and these calls were filtered to coordinates with ≥8× coverage and consensus quality ≥ 20.
Indels affecting coding sequences were identified as previously described 3 , but we used phaster instead of cross_match and Maq. Specifically, unmapped reads from Maq were aligned to the reference sequence using phaster (version 1.100122a) with the parameters -max_ins:21 -max_del:21 -gapextend_ins:-1 -gapextend_del:-1 -match_report_type:1. Reads were then filtered for those with at most two substitutions and one indel. Reads that mapped to the negative strand were reverse complemented and, together with the other filtered reads, were remapped using the same parameters to reduce ambiguity in the called indel positions. These reads were then filtered for (i) having a single indel more than 3 bp from the ends and (ii) having no other substitutions in the read. Putative indels were then called per individual if they were supported by at least two filtered reads that started from different positions. An 'indel reference' was generated as previously described 3 , and all the reads from each individual were mapped back to this reference using phaster with default settings and -match_report_type:1. Indel genotypes were called as previously described 3 .
To determine the novelty of the variants, sequence calls were compared against 16 individuals for whom we had previously reported exome data 2,3 and 10 EGP exomes. Annotations of variants were based on NCBI and UCSC databases using an in-house server (SeattleSeqAnnotation). Loss-of-function variants were defined as nonsense mutations (premature stop) or frame-shifting indels. For each variant, we also generated constraint scores as implemented in GERP 10 .
Post hoc ranking of candidate genes. Candidate genes were ranked by summation of a case score and variant score. The case score was calculated by counting the total number of Kabuki exomes in which a variant was identified at a given gene, weighted for case rank from 1 to 10. For example, the top ranked case was weighted by a factor of 10, whereas the case ranked tenth was weighted by a factor of 1. The variant score was calculated by first counting the total number of nonsense, nonsynonymous and synonymous variants across the ten Kabuki exomes and assigning a prior probability of the occurrence of each variant type per gene based upon the target of 18,918 genes. Next, for each candidate gene shared among two or more Kabuki exomes, the scores for each newly identified variant were summed across the gene. The case score and variant score were summed as the candidate gene score.
Mutation validation.
Sanger sequencing of PCR amplicons from genomic DNA was used to confirm the presence and identity of variants in the candidate gene identified via exome sequencing and to screen the candidate gene in additional individuals with Kabuki syndrome.
Array comparative genomic hybridization (CGH).
Samples were hybridized to commercially available whole-genome tiling arrays consisting of one million oligonucleotide probes with an average spacing of 2.6 kb throughout the genome (SurePrint G3 Human CGH Microarray 1x1M, Agilent Technologies). Twenty-one probes on this array covered MLL2 specifically. Data were analyzed using Genomics Workbench software according to the manufacturer's instructions.
